Scholarlink

<p>Acute kidney injury (AKI) is a prevalent clinical syndrome among hospitalized patients, affecting 20–30% of inpatients, with mortality rates exceeding 50% in ICU settings. The HALP score (hemoglobin, albumin, lymphocyte, and platelet), a composite biomarker reflecting inflammatory and nutritional status, has shown prognostic value across various conditions, while the application of the HALP score in AKI remains underexplored. In this study, a total of 1,005 patients with AKI were included. Fine-Gray competing risk models were employed for the primary analysis, with the robustness of the findings assessed through cumulative incidence function (CIF) curves and sensitivity analyses. After adjusting for confounders, a higher HALP score was significantly associated with partial recovery and complete recovery. The Q4 group also demonstrated the lowest cumulative risk of therapy cessation (Day 21: 11.0%), with significantly reduced risks observed in Q3 (SHR 0.66) and Q4 (SHR 0.39). Taken together, the HALP score is significantly associated with renal recovery and therapy cessation in patients with AKI and may serve as a convenient tool for risk stratification, thereby complementing personalized treatment decisions.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Association between HALP score and in-hospital outcomes in patients with acute kidney injury: a retrospective cohort study

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年5月29日

查看全文
  • Fulian Lin,
  • Zhihui Chen,
  • Tong Zhou,
  • Jincheng Tang,
  • Heping Zhang

摘要

Acute kidney injury (AKI) is a prevalent clinical syndrome among hospitalized patients, affecting 20–30% of inpatients, with mortality rates exceeding 50% in ICU settings. The HALP score (hemoglobin, albumin, lymphocyte, and platelet), a composite biomarker reflecting inflammatory and nutritional status, has shown prognostic value across various conditions, while the application of the HALP score in AKI remains underexplored. In this study, a total of 1,005 patients with AKI were included. Fine-Gray competing risk models were employed for the primary analysis, with the robustness of the findings assessed through cumulative incidence function (CIF) curves and sensitivity analyses. After adjusting for confounders, a higher HALP score was significantly associated with partial recovery and complete recovery. The Q4 group also demonstrated the lowest cumulative risk of therapy cessation (Day 21: 11.0%), with significantly reduced risks observed in Q3 (SHR 0.66) and Q4 (SHR 0.39). Taken together, the HALP score is significantly associated with renal recovery and therapy cessation in patients with AKI and may serve as a convenient tool for risk stratification, thereby complementing personalized treatment decisions.